17:14 , May 24, 2018 |  BC Extra  |  Financial News

Melinta raises $110M in follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $110 million through the sale of 22 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The price is a 32% discount...
21:55 , Dec 1, 2017 |  BC Week In Review  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
00:16 , Nov 30, 2017 |  BC Extra  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
14:46 , Aug 11, 2017 |  BC Week In Review  |  Company News

Melinta goes public by acquiring majority of Cempra

Melinta Therapeutics Inc. (New Haven, Conn.) has found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc. (NASDAQ:CEMP). The combined company will retain Melinta's name and will be...
21:30 , Aug 9, 2017 |  BC Extra  |  Company News

Melinta goes public by acquiring majority of Cempra

Melinta Therapeutics Inc. (New Haven, Conn.) has found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc. (NASDAQ:CEMP). The combined company will retain Melinta's name and will be...
19:11 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

FDA approves Melinta's Baxdela for ABSSSIs

FDA approved oral and IV Baxdela delafloxacin (RX-3341) from Melinta Therapeutics Inc. (New Haven, Conn.) to treat acute bacterial skin and skin structure infections (ABSSSIs). Baxdela’s label includes a boxed warning that notes the risks...
19:26 , Jun 20, 2017 |  BC Extra  |  Company News

FDA approves Melinta’s fluoroquinolone antibiotic

FDA approved oral and IV Baxdela delafloxacin from Melinta Therapeutics Inc. (New Haven, Conn.) to treat acute bacterial skin and skin structure infections (ABSSSIs). Baxdela’s label includes a boxed warning that notes the risks of...
19:37 , Mar 10, 2017 |  BC Week In Review  |  Company News

Melinta, Menarini deal

Melinta granted Menarini exclusive rights to develop and commercialize oral and IV delafloxacin in 68 countries, including Europe, the Commonwealth of Independent States and Asia-Pacific, excluding Japan. Both formulations of delafloxacin are under FDA review...
20:18 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

IV Baxdela regulatory update

FDA said it does not plan to hold advisory committee meetings for two NDAs from Melinta under Priority Review for IV and oral Baxdela delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSIs)....
21:35 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

IV Baxdela regulatory update

FDA accepted and granted Priority Review to NDAs for IV and oral Baxdela delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are June 19. The broad-spectrum fluoroquinolone antibiotic has...